Tosca Camille Seibert Guiao
Philippine Christian University, PhilippinesTitle: Validation of a lateral flow immunoassay for the detection of IgG/IgM antibodies to SARS COV2 - COVID 19 among symptomatic and asymptomatic high risk OBGYN patients in selected hospitals in Olongapo City and Zambales - A multicenter prospective study
Abstract
As the world face health system shocks from coronavirus disease 2019 (COVID-19), an emerging infectious disease caused yet by a novel pathogen (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), Obstetrician-gynecologists became perplexed by the uncertainties it may bring to each pregnant women and the rest of the vulnerable gynecologic population. Despite the caveats of the CDC study, the susceptibility of a severe covid19 symptoms poses a “signal” to all pregnant women. On the other hand, high risk gynecologic patient such as cancer patients report high fatality rates due to Covid-19.
The country’s initial Capacity for acute diagnosis via RTPCR testing consist of only tiny aperture of the population, Case finding strategies through centralised specialist laboratories were mostly limited to patients admitted to hospital with moderate to severe symptoms. Indeed, a substantial proportion of asymptomatic pregnant women and gynecologic cancer patients often get de-prioritized due to limited testing kits. The case reporting in these cases, while important, becomes less of a priority. Missed opportunity occurs whenever we fail to test people who might be asymptomatic COVID-19 carriers. Hence, came the approval of rapid based antibody test kits by Department of Health to serve as an adjunct to the diagnosis Covid19 with a short turnaround time compared to the RTPCR.
With the intent of coming up a less expensive fast point of care test kits, antibody-based lateral flow assays were developed to test for IgM and IgG antibodies. These tests to detect antibody responses to Covid19 may add to our understanding of the extent of infecion among people who are not identified through active case finding and surveillance efforts. This paper aims to determine the accuracy of antibody tests for presence of IgM and IgG antibodies as an adjunct to RT- PCR for diagnosis of COVID-19 among high risk OBGYN patients.
Biography
WILL BE UPDATED SOON
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
gynaecology@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration query
finance@scientexconferences.com
gynaecology@scientexevents.org
Our Social Presence
Call us at
USA :(+1) 202 773 8420